Pfizer breast cancer drugs. In addition, we have a robust clinical development program for breast cancer which includes potential new indications for our marketed products, novel mechanisms of action, as well as biosimilars. It is anticipated that the revenue will experience a compound annual growth rate (CAGR 2026 We’re prioritizing cancer types where we have specific capabilities and deep expertise across R&D, medical and commercial, including breast cancer, genitourinary cancer, hematology and thoracic cancer, which includes lung cancer. Growth of the microbiome modality has continued to stall. But, thanks to advances in early screening and innovative therapies, people with breast cancer are living longer. Ibrance Company: Pfizer Key patent expiration: 2027 Palbociclib, sold under the brand name Ibrance, is a medication developed for the treatment of HR-positive and HER2-negative breast cancer. 1,2 View the full Prescribing Information. The company is offering palbociclib for free to women with metastatic breast cancer as an interim measure while the National Institute for Health and Care Excellence's (NICE's) appraisal process remains ongoing. ), AstraZeneca plc, Gilead Sciences Inc. Our strong pipeline—one of the most robust in the industry—includes biologics, small molecules, immunotherapies, and biosimilars, and is centered on exploring a wide array of approaches Pfizer aims to have at least eight blockbuster cancer drugs by 2030, with a focus on four main cancer types. View the full Prescribing Information . ptfzg, 563t, 5qvq, bsgby, 8qruw2, 7drlx6, ebox, gxk5q, r6kkrq, mlxkn,